Document Detail

QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  10356598     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To investigate effects of doxorubicin therapy on cardiac electrophysiology, with special emphasis on QT dispersion and late potentials, in lymphoma patients. DESIGN: Prospective study. SETTING: University hospital. SUBJECTS: Twenty-eight adult non-Hodgkin's lymphoma patients who received doxorubicin to a cumulative dose of 400-500 mg m-2. MAIN OUTCOME MEASURES: Standard 12-lead electrocardiogram (ECG) and signal-averaged ECG (SAECG) recordings were performed at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg m-2. RESULTS: Heart rate-corrected QT interval (QTc) increased from 402 +/- 4 to 416 +/- 5 ms (P = 0.002) during the study period. QT dispersion (variability in QT interval duration amongst the different leads of the standard 12-lead ECG) increased from 24.1 +/- 2.5 to 35.0 +/- 2.8 ms (P = 0.041) and QTc dispersion increased from 26.5 +/- 2.5 to 39.0 +/- 3.5 ms (P = 0.039). Five patients (18%) developed QT dispersion exceeding 50 ms. In addition, two patients (7%) developed late potentials during doxorubicin therapy. The changes in QTc duration, QT dispersion and late potentials occurred independently of the impairment of left ventricular function. CONCLUSIONS: Prolongation of QTc, increased QT dispersion and development of late potentials are indicative of doxorubicin-induced abnormal ventricular depolarization and repolarization. QT dispersion and late potentials are both known to be associated with increased risk of serious ventricular dysrhythmias and sudden death in various cardiac diseases. Thus, follow-up of these parameters might also be useful in assessing the risk of late cardiovascular events in cancer patients treated with anthracyclines.
T Nousiainen; E Vanninen; A Rantala; E Jantunen; J Hartikainen
Related Documents :
18956158 - long term electrocardiography (holter monitoring)
7888258 - Increased dispersion of refractoriness in the absence of qt prolongation in patients wi...
17640478 - Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in c...
19305408 - Common variants at ten loci influence qt interval duration in the qtgen study.
8237518 - Ischemic cardiopathy and other heart diseases: differences in carotid atheromas examine...
19055978 - Outpatient neuroimaging of stroke.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of internal medicine     Volume:  245     ISSN:  0954-6820     ISO Abbreviation:  J. Intern. Med.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-06-16     Completed Date:  1999-06-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8904841     Medline TA:  J Intern Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  359-64     Citation Subset:  IM    
Department of Medicine, Kuopio University Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / adverse effects*,  therapeutic use
Doxorubicin / adverse effects*,  therapeutic use
Electrocardiography / drug effects
Heart Conduction System / drug effects*
Lymphoma, Non-Hodgkin / drug therapy*,  physiopathology
Middle Aged
Prospective Studies
Signal Processing, Computer-Assisted
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bronchoalveolar lavage cells from sarcoidosis patients and healthy controls can efficiently present ...
Next Document:  Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thr...